The demand for otitis media treatment exists everywhere in the world, so the market is very large if regulatory approval is obtained. In the United States, Europe, etc., there are already permanent chemical substances (PFAS) – Oh, it's not PFAS here, it's otitis media. I stand corrected. – Globally, more than 80% of children have otitis media at least once before the age of 3, so it is universal.
Earflo is currently awaiting FDA 510(k) approval, and its safety and efficacy have been proven in clinical studies, so global expansion is likely after approval. In terms of regulation, it is classified as a medical device Class II, so it must be certified in each country, but it is expected to be relatively easy because it is not invasive.
In addition, this technology can be applied to other markets such as relieving ear barotrauma that occurs during airplane take-off and landing in adults, or ear pressure regulation training for divers/pilots. However, realistically, the largest market is for infants and young children, and there is room for expansion by diversifying the product lineup into mask forms in addition to cup forms to expand the applicable age range.
Overall, Earflo is a solution with the potential to impact the global pediatric market without specific national or environmental constraints.